Liothyronine Sodium |
رقم الكتالوجGC12409
One-Click Copy Product Info
|
ليوثيرونين الصوديوم هو شكل نشط من هرمون الغدة الدرقية
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55-06-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Liothyronine sodium is a potent thyroid hormone receptor TRα and TRβ agonist with Ki values of 2.33nM[1]. Liothyronine sodium is an active form of thyroid hormone that is chemically almost identical to the endogenous thyroid hormone triiodothyronine (T3)[2]. Liothyronine sodium is usually used in the replacement treatment of hypothyroidism[3], and can also be used in the treatment of thyroid cancer and the detection of thyroid function[4]. In addition, Liothyronine sodium is also used in the study of other metabolic related diseases, such as obesity[5].
In vitro, Liothyronine sodium(100µM) treatment of Jurkat hTIGIT cells and CHOK1-hPVR cells for 48h reversed the IL-2 secretion inhibition resulted by TIGIT/PVR ligation without affecting cell viability[6]. Liothyronine sodium(100nM) stimulates the proliferation of hepatocellular carcinoma cells overexpressing TRβ1[1].
In vivo, Liothyronine sodium(25μg/kg; 1h post-tMCAO; intravenously) reduced infarct volumes in a dose-dependent manner, with reduced efficacy at 4.5h post-tMCAO(P = 0.066) and no effect at 8h post-tMCAO(P > 0.999), while demonstrating a persistent protective effect for 72h post-tMCAO (P < 0.01) and accelerating motor function recovery by day 3 (P < 0.05), accompanied by reduced cerebral edema, diminished blood–brain barrier leakage, and decreased aquaporin-4 expression in stroke mice[7].
References:
[1] Lin, K. H., Lin, Y. W., Parkison, C., & Cheng, S. Y. (1994). Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer letters, 85(2), 189–194.
[2] MORTON J. H. (1957). Sodium liothyronine in metabolic insufficiency syndrome and associated disorders; preliminary report. Journal of the American Medical Association, 165(2), 124–129.
[3] Escobar-Morreale, H. F., Botella-Carretero, J. I., & Morreale de Escobar, G. (2015). Treatment of hypothyroidism with levothyroxine or a combination of levothyroxine plus L-triiodothyronine. Best practice & research. Clinical endocrinology & metabolism, 29(1), 57–75.
[4] Salas-Lucia, F., & Bianco, A. C. (2022). T3 levels and thyroid hormone signaling. Frontiers in endocrinology, 13, 1044691.
[5] Krotkiewski M. (2000). Thyroid hormones and treatment of obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 24 Suppl 2, S116–S119.
[6] Zhou, X., Du, J., Wang, H., Chen, C., Jiao, L., Cheng, X., Zhou, X., Chen, S., Gou, S., Zhao, W., Zhai, W., Chen, J., & Gao, Y. (2020). Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Cell communication and signaling : CCS, 18(1), 142.
[7] Ullrich, D., Führer, D., Heuer, H., Mayerl, S., Haupeltshofer, S., Schmitt, L. I., Leo, M., Szepanowski, R. D., Hagenacker, T., Schwaninger, M., Kleinschnitz, C., & Langhauser, F. (2025). Triiodothyronine treatment in mice improves stroke outcome and reduces blood-brain barrier damage. European thyroid journal, 14(1), e240143.
| Cell experiment [1]: | |
Cell lines | Jurkat-hTIGIT and CHOK1-hPVR cells |
Preparation Method | CHOK1-hPVR were seeded into 24- well plates at a density of 1 × 105 cells/well and allowed for cell adhesion. Jurkat-hTIGIT were added into the plates pre-cultured with CHOK1-hPVR at a density of 2 × 105 cells/well with the effector: target ratio of 2:1. Jurkat-hTIGIT cells were stimulated with the anti-human CD3 (1μg/mL) and anti-human CD28 (0.5μg/mL). Liothyronine sodium(100μM) were added in the coculture system, and a functional anti-TIGIT antibody served as the positive control. After 44h of coculture, the protein transport inhibitor was added and incubated for another 4h. Then the cells were harvested, washed, and followed by fixation and permeabilization. Afterwards, the permeabilized JurkathTIGIT cells were stained with anti-human IL-2 APC or isotype control antibody for 30min at 4°C. |
Reaction Conditions | 100μM; 48h |
Applications | Liothyronine sodium could reverse the IL-2 secretion inhibition resulted by TIGIT/PVR ligation without affecting the proliferation of tumor cells. |
| Animal experiment [2]: | |
Animal models | C57BL/6N mice |
Preparation Method | Mice received Liothyronine sodium at doses of either 10, 25, or 50μg/kg bw. Stock solution (10mg/ml in 1 M HCl:EtOH (1:4)) was diluted in 0.9% NaCl and intravenously injected via the tail vein, either 1h prior to tMCAO induction or 1, 4.5, or 8h after tMCAO induction. As control, mice received equivalent volumes of 0.9% NaCl. Functional assessment was conducted 24 or 72h post tMCAO. Mice were sacrificed 24 or 72h after tMCAO and brains were removed for Western blot or histological analysis. |
Dosage form | 10, 25, or 50μg/kg; 24 or 72h; intravenously injected via the tail vein |
Applications | Liothyronine sodium (25μg/kg, 1h post-tMCAO, intravenously) reduced infarct volumes in a dose-dependent manner, with reduced efficacy at 4.5h post-tMCAO(P = 0.066) and no effect at 8h post-tMCAO(P > 0.999), while demonstrating a persistent protective effect for 72h post-tMCAO (P < 0.01) and accelerating motor function recovery by day 3 (P < 0.05), accompanied by reduced cerebral edema, diminished blood–brain barrier leakage, and decreased aquaporin-4 expression in stroke mice. |
References: | |
| Cas No. | 55-06-1 | SDF | |
| Chemical Name | sodium;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate | ||
| Canonical SMILES | C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)[O-])N)I)I)O.[Na+] | ||
| Formula | C15H12I3NO4.Na | M.Wt | 672.96 |
| الذوبان | ≥ 23.47 mg/mL in DMSO with ultrasonic and warming | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.486 mL | 7.4299 mL | 14.8597 mL |
| 5 mM | 297.2 μL | 1.486 mL | 2.9719 mL |
| 10 mM | 148.6 μL | 743 μL | 1.486 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)